Ac immune announces first positive cognitive results for a tau-targeting monoclonal antibody in alzheimer's disease

Top-line data from lauriet phase 2 trial of semorinemab in mild-to-moderate ad shows a statistically significant reduction on one of two co-primary endpoints, adas-cog11

ACIU Ratings Summary

ACIU Quant Ranking